ArticleOncotarget2017
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Trial
- Systemic Protein Biomarkers, Composite Blood Inflammatory Indices and Cellular Ratios in Metastatic Colorectal Cancer: Potential Therapeutic Targets.Diseases (Basel, Switzerland) · 2026Article
- Neutrophil-to-lymphocyte ratio is associated with early cervical shortening after cerclage: a single-center cohort study integrating C-reactive protein.Frontiers in medicine · 2026Article
- Article
- Prognostic Nutritional Index is Related to All-Cause Mortality in Patients With Stage IV Colorectal Cancer Treated With Capecitabine: Single-Center 24-Month Observational Study in Vietnam.Journal of clinical laboratory analysis · 2024Observational
- Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.Scientific reports · 2024Article
- Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.Journal for immunotherapy of cancer · 2023Article
- Therapeutic Potential of a Small-Molecule STAT3 Inhibitor in a Mouse Model of Colitis.Cancers · 2023Article
- The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2022Article
- High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer.World journal of clinical cases · 2022Article
- Research Progress on the Relationship Between Inflammation and Colorectal Cancer.Annals of gastroenterological surgery · 2022Review
- Article
- Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.Therapeutic advances in medical oncology · 2021Article
- Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer.Annals of surgical treatment and research · 2021Article
- Article
- External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.Cancer medicine · 2020Article
- Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.Scientific reports · 2020Observational
- Article
- Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.International journal of clinical oncology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory biomarkers are useful prognostic tools in cancer patients. However, the prognostic and predictive value of inflammatory biomarkers beyond the 1
resultsIn multivariate analysis 1 standard deviation increase in neutrophil-lymphocyte-ratio (NLR) was associated with an 8.5% absolute lower objective-response-rate (ORR) in 1
methodsTwo-hundred-fifty-eight patients with mCRC undergoing palliative chemo(immuno-)therapy were retrospectively included. Primary endpoints were 6-month PFS and ORR during 1st-line, 2nd-line, and 3rd-line treatment, and 6-month overall survival during BSC.
conclusionThis study shows that inflammatory biomarkers are useful predictors of disease outcome and treatment response over several treatment lines in mCRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.